Italia markets closed

Dow Jones
39.880,02
-123,57(-0,31%)
Nasdaq
16.785,46
+99,49(+0,60%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0867
-0,0005(-0,04%)
Bitcoin EUR
62.888,80
+1.459,62(+2,38%)
CMC Crypto 200
1.388,17
+33,76(+2,49%)

NBIX Dec 2024 110.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,4000

0,0000

(0,00%)

In data: 10:51AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat